ISPIC - Image-Guided Surgery and Personalised Postoperative Immunotherapy to Improving Cancer Outcome

    TRAINING Of Early Stage Researchers (ESRs)
    • Train the next generation of researchers and technical experts in order to provide a critical mass to promote research and development in the field of image guided surgery (IGS) and adjuvant immunotherapy in the field of oncology.
    • Improve the career perspectives of researchers by
      • maximising their technical and soft skill base for a highly inter-disciplinary field
      • providing skills to match public and private sector needs
      • delivering excellence in doctoral/early-stage research training by involving key European players, both academic and industrial.

    • Positive patient outcome: better overall survival and quality of life (QOL) for the patient.
    • QOL - less invasive surgery and personalized immunotherapy on biomaterial carriers
    • Economic - avoid unnecessary or to perform less invasive surgery which would lead to reduced hospital stays and less complications. Personalised medicine for prolonged disease-free survival. Both surgery and optimised adjuvant immunotherapy will therefore give an overall survival benefit across all different stages of cancer, which means fewer burdens upon healthcare service providers.
    • Reduce the chances of recurrence as adjuvant combination immunotherapy will be implemented to optimally recruit the hosts‟ own immune system to eradicate distal metastases, where immune gene signatures will be used to monitor efficacy of treatment

    • Create a highly inter-disciplinary and intersectoral cross-training programme in a cutting-edge field of research.
    • Leverage previously generated knowledge in the here described field and foster long-term collaboration between key European academic groups and small medium sized entities (SMEs).
    • Build cooperation and networking right into the post-graduate training and research curriculum.
    • Optimised strategy for cancer management during and after surgery
    • Targeted surgical resection - precision optically-guided surgery, aiming at complete resection of the tumour.
    • State-of-art computational approaches to identify new biomarkers / gene signatures - A novel machine learning algorithm, t-Distributed Stochastic Neighbour Embedding (t-SNE), for dimensionality reduction that is particularly well suited for the visualization of high-dimensional datasets.
    • New preclinical models with immunological relevance – easy translation of protocols from preclinical studies to humans
    • Fluorescence and Magnetic Resonance Imaging (MRI) - tracking of immune activity in vivo by labelling of T-cells, and macrophages (MQs)
    • Optimised postoperative (adjuvant) immunotherapy – versatility in design of the immunotherapy by use of biomaterial-based technologies to take us towards more personalised medicine in the treatment of cancer.

    • Recruit 20 ESRs and train them according to a highly structured, interdisciplinary and integrated training plan.
    • Provide the necessary core skills for the WPs through targeted workshops held throughout the network
    • Mentor researchers by career guidance arrangements and transferable skill training
    • Promote collaboration by mobility through secondments (SECs) across countries and disciplines

    • Fluorescence-labelled intraoperative tumour-margin specific probe.
    • Immune gene signatures to better predict disease progression and treatment outcome.
    • Specific combined immunotherapy so that we can improve patient outcome and survival.
    • Biomaterial-based (Nanoparticle [NP] or Microparticle [MP]) encapsulated library of defined multi-component immunotherapeutic biomolecules.